Sort by
Keyphrases
Novel Therapeutics
100%
Interleukin-6 Signaling
100%
Spinal Cord Injury Pain
100%
Interleukin-6
72%
Glutamate Transporter 1 (GLT-1)
27%
Mechanical Allodynia
18%
Analgesic Effect
18%
Reactive Astrocytes
18%
Interleukin-6 Levels
18%
Tocilizumab
18%
Contusion Model
9%
Hindlimb
9%
Rheumatoid Arthritis
9%
Allodynia
9%
Immunocytochemistry
9%
Dorsal Root Ganglion
9%
Lesion Site
9%
Clinically Significant
9%
Western Blot
9%
Weight Loss
9%
Protein Level
9%
Systemic Injection
9%
Effective Treatment
9%
Astrocytes
9%
Humanized
9%
Lumbar
9%
Gabapentin
9%
Astrocytic
9%
Associated Weights
9%
Lumbar Segment
9%
Interleukin-6 Inhibitors
9%
Neuroscience
Interleukin 6
100%
Spinal Cord Injury
100%
Allodynia
27%
Astrocyte
27%
Tocilizumab
18%
Receptor Antibody
9%
Immunocytochemistry
9%
Dorsal Root Ganglion
9%
Interleukin-6 Receptor
9%
Western Blot
9%
Gabapentin
9%
Rheumatoid Arthritis
9%
Glutamate Transporter
9%
Pharmacology, Toxicology and Pharmaceutical Science
Spinal Cord Injury
100%
Interleukin 6
100%
Analgesic Agent
18%
Mechanical Allodynia
18%
Tocilizumab
18%
Western Blot
9%
Allodynia
9%
Contusion
9%
Interleukin 6 Receptor
9%
Rheumatoid Arthritis
9%
Gabapentin
9%
Receptor Antibody
9%
Glutamate Transporter
9%
Inflammatory Arthritis
9%
Immunology and Microbiology
Spinal Cord
100%
Interleukin 6
100%
Astrocyte
27%
Analgesic Activity
18%
Tocilizumab
18%
Ganglion
9%
Limb
9%
Western Blot
9%
Dorsal Root
9%
Interleukin-6 Receptor
9%
Immunocytochemistry
9%
Inflammatory Arthritis
9%
Receptor Antibody
9%